Impella Real-World Surveillance of Patients Using Sodium Bicarbonate

CompletedOBSERVATIONAL
Enrollment

312

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Cardiogenic ShockHigh Risk PCI
Interventions
DEVICE

Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution

US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.

DEVICE

Impella RP with Sodium Bicarbonate used as purge solution

US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.

Trial Locations (20)

15213

UPMC Presbyterian, Pittsburgh

32804

Advent Helath Orlando, Orlando

33606

Tampa General Hospital, Tampa

35233

University of Alabama, Birmingham

45219

Christ Hospital, Cincinnatti

48202

Henry Ford, Detroit

48236

Ascension St. John Hospital, Detroit

59802

Providence St. Patrick, Missoula

68105

University of Nebraska, Omaha

72211

Arkansas Heart Hospital, Little Rock

75093

The Heart Hospital Baylor Plano, Plano

75226

Baylor Scott and White (Baylor Heart and Vascular), Dallas

85712

Pima Heart and Vascular (Tuscon Medical Center), Tucson

90033

Keck USC Medical Center, Los Angeles

97205

Montefiore Medical Center - Moses, Portland

97227

Legacy Emanuel, Portland

97239

Oregon Health & Science University, Portland

98405

MultiCare Tacoma General, Tacoma

99204

Providence Sacred Heart, Spokane

08901

Robert Wood Johnson University Hospital, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abiomed Inc.

INDUSTRY